These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26906711)

  • 21. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical utility of bone marker measurements in osteoporosis.
    Wheater G; Elshahaly M; Tuck SP; Datta HK; van Laar JM
    J Transl Med; 2013 Aug; 11():201. PubMed ID: 23984630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis (2018 Edition).
    Nishizawa Y; Miura M; Ichimura S; Inaba M; Imanishi Y; Shiraki M; Takada J; Chaki O; Hagino H; Fukunaga M; Fujiwara S; Miki T; Yoshimura N; Ohta H;
    Clin Chim Acta; 2019 Nov; 498():101-107. PubMed ID: 31425674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining information from multiple bone turnover markers as diagnostic indices for osteoporosis using support vector machines.
    Zhang T; Liu P; Zhang Y; Wang W; Lu Y; Xi M; Duan S; Guan F
    Biomarkers; 2019 Mar; 24(2):120-126. PubMed ID: 30442069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical usefulness of bone turnover markers with the treatment of osteoporosis].
    Miura M
    Clin Calcium; 2014 Mar; 24(3):367-76. PubMed ID: 24576933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis.
    Eastell R; Reid DM; Vukicevic S; Ensrud KE; LaCroix AZ; Thompson JR; Thompson DD; Cummings SR
    Bone; 2012 May; 50(5):1135-40. PubMed ID: 22348983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reference intervals for bone turnover markers and their association with incident hip fractures in older men: the Health in Men study.
    Chubb SA; Byrnes E; Manning L; Beilby JP; Ebeling PR; Vasikaran SD; Golledge J; Flicker L; Yeap BB
    J Clin Endocrinol Metab; 2015 Jan; 100(1):90-9. PubMed ID: 25322270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?
    Eastell R; Pigott T; Gossiel F; Naylor KE; Walsh JS; Peel NFA
    Eur J Endocrinol; 2018 Jan; 178(1):R19-R31. PubMed ID: 29046326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bone turnover marker].
    Miura M; Satoh Y
    Nihon Rinsho; 2015 Oct; 73(10):1649-58. PubMed ID: 26529926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone turnover markers in the management of postmenopausal osteoporosis.
    Brown JP; Albert C; Nassar BA; Adachi JD; Cole D; Davison KS; Dooley KC; Don-Wauchope A; Douville P; Hanley DA; Jamal SA; Josse R; Kaiser S; Krahn J; Krause R; Kremer R; Lepage R; Letendre E; Morin S; Ooi DS; Papaioaonnou A; Ste-Marie LG
    Clin Biochem; 2009 Jul; 42(10-11):929-42. PubMed ID: 19362543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of bone metabolic markers in qualification for treatment of osteoporosis. Results of POMOST study].
    Przedlacki J; Bartoszewicz Z; Ksiezopolska-Orłowska K; Kondracka A; Grodzki A; Bartuszek T; Bartuszek D; Swirski A; Loth E; Musiał J; Luczak E; Teter P; Lasiewicki A; Walkiewicz A; Drozdowska-Rusinowicz I
    Endokrynol Pol; 2009; 60(1):25-32. PubMed ID: 19224502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
    Bonnick SL; Shulman L
    Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study.
    Szulc P; Montella A; Delmas PD
    Ann Rheum Dis; 2008 Sep; 67(9):1249-55. PubMed ID: 18065499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of biochemical markers of bone turnover in osteoporosis.
    Allende-Vigo MZ
    P R Health Sci J; 2007 Jun; 26(2):91-5. PubMed ID: 17722420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical use of serum and urine bone markers in the management of osteoporosis.
    Srivastava AK; Vliet EL; Lewiecki EM; Maricic M; Abdelmalek A; Gluck O; Baylink DJ
    Curr Med Res Opin; 2005 Jul; 21(7):1015-26. PubMed ID: 16004668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A; Glover SJ; Eastell R
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Application of Bone Turnover Markers in Osteoporosis in Korea.
    Park SY; Ahn SH; Yoo JI; Chung YJ; Jeon YK; Yoon BH; Kim HY; Lee SH; Lee J; Hong S
    J Bone Metab; 2019 Feb; 26(1):19-24. PubMed ID: 30899720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone turnover markers in sheep and goat: A review of the scientific literature.
    Camassa JA; Diogo CC; Sousa CP; Azevedo JT; Viegas CA; Reis RL; Dourado N; Dias IR
    An Acad Bras Cienc; 2017; 89(1):231-245. PubMed ID: 28273244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical markers of bone remodeling.
    Kleerekoper M
    Am J Med Sci; 1996 Dec; 312(6):270-7. PubMed ID: 8969616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.